Severe hypoglycemia rates and associated costs among type 2 diabetics starting basal insulin therapy in the United States.

The article presents brief information on the hypoglycemia rates and associated costs among type 2 diabetics with basal insulin therapy in the U.S. It states that hypoglycemic people with type 2 diabetes mellitus (T2D) will be diagnosed, and differences in SH rates and costs stratified by history of prior SH events will be examined to derive current real-world data on the rates and costs of severe hypoglycemia.